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Abstract
Background: Bartonella henselae is the zoonotic agent of cat scratch disease and causes potentially fatal infections in
immunocompromised patients. Understanding the complex interactions between the host’s immune system and bacterial
pathogens is central to the field of infectious diseases and to the development of effective diagnostics and vaccines.
Methodology: We report the development of a microarray comprised of proteins expressed from 96% (1433/1493) of the
predicted ORFs encoded by the genome of the zoonotic pathogen Bartonella henselae. The array was probed with a
collection of 62 uninfected, 62 infected, and 8 ‘‘specific-pathogen free’’ naı ¨ve cat sera, to profile the antibody repertoire
elicited during natural Bartonella henselae infection.
Conclusions: We found that 7.3% of the B. henselae proteins on the microarray were seroreactive and that seroreactivity was
not evenly distributed between predicted protein function or subcellular localization. Membrane proteins were significantly
most likely to be seroreactive, although only 23% of the membrane proteins were reactive. Conversely, we found that
proteins involved in amino acid transport and metabolism were significantly underrepresented and did not contain any
seroreactive antigens. Of all seroreactive antigens, 52 were differentially reactive with sera from infected cats, and 53 were
equally reactive with sera from infected and uninfected cats. Thirteen of the seroreactive antigens were found to be
differentially seroreactive between B. henselae type I and type II. Based on these results, we developed a classifier algorithm
that was capable of accurately discerning 93% of the infected animals using the microarray platform. The seroreactivity and
diagnostic potential of these antigens was then validated on an immunostrip platform, which correctly identified 98% of the
infected cats. Our protein microarray platform provides a high-throughput, comprehensive analysis of the feline humoral
immune response to natural infection with the alpha-proteobacterium B. henselae at an antigen-specific, sera-specific, and
genome-wide level. Furthermore, these results provide novel insight and utility in diagnostics, vaccine development, and
understanding of host-pathogen interaction.
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Introduction
Controlling Bartonella infection in its cat reservoir is integral to
preventing cat scratch disease (CSD) in humans. B. henselae
infection is mainly asymptomatic in cats, but has been associated
with kidney disease and urinary tract infections, stomatitis, and
lymphadenopathy [1]. The prevalence of Bartonella infection in cats
ranges from 25% to as high as 41% throughout the world [2].
Infected cats can have bacterial titers of .10
6 colony forming units
(CFU)/ml of blood and can remain bacteremic for several months
to several years. Cats that are bacteremic, especially with high
titers, are more likely to infect humans by scratches or bites.
Although antibiotic treatment of infected cats has been associated
with reduction of bacteremia levels, treatment does not appear to
be sufficient to completely eradicate B. henselae from the blood
stream [3]. Indeed, treatment can result in increased transmission
of B. henselae to humans during attempts to administer antibiotics
pills to uncooperative, infected cats.
Preventing initial infection of cats by vaccination is a potential
strategy for limiting B. henselae infections in humans. With an
estimated 90 million pet cats in the US and a predicted 8–20
million cats with chronic bacteremia, prevention and reduction of
morbidity in humans from CSD could be achieved through
extensive cat vaccination programs [4]. Profiling the feline host
antibody response to B. henselae infection is central to diagnostics
development and the identification of potential subunit vaccine
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henselae that can cause CSD in humans: types I (Houston); and II
(Marseille) [5]. Cats are most often infected with one or the other
type, but some cats are co-infected with both types, and both types
can be transmitted to humans from pets [5]. Thus, establishing
and comparing the host immune profile to infection with both
types may be necessary for optimizing candidate antigen selection
to prevent feline infection with type I and type II.
We previously developed a protein microarray technology that
allows construction of the complete predicted proteome of a
microorganism [6,7,8,9,10]. Utilization of arrays constructed from
in vitro transcription reactions can identify the repertoire of
seroreactive antibodies to proteins encoded by an infectious agent.
These arrays are limited to detection of antibodies against
recombinant proteins and would not detect post-translational
modifications and non-protein antigens [11]. However, these
arrays can be utilized to address basic questions about the pattern
of the host humoral immune response to infectious agents
[12,13,14], and to identify individual antigens that could be used
as diagnostic reagents or for inclusion in vaccines [6,15]. The data
derived from these studies can also be used to evaluate and
improve the accuracy of in silico predictions of seroreactive
antigens, and can provide a more detailed understanding of the
adaptive immune response to infection. In this study, we
developed a B. henselae genome-wide protein array and used the
arrays to profile the antibody response in naturally infected cats
and uninfected cats.
Materials and Methods
Bacterial strains
DNA extracted from B. henselae wild type strain JK33R was used
for template DNA from which all ORFs were amplified prior to
cloning. This B. henselae strain was isolated from the blood of an
AIDS patient with bacillary angiomatosis and was cryopreserved
after only several passages on agar. JK33R retains the rough
colony phenotype characteristic of primary B. henselae isolates
obtained from human and feline blood.
Cat serum samples
All procedures involving animals followed NIH protocols and
were approved by and performed according to guidelines of the
Institutional Animal Care and Use Committee of University of
California, Davis. Serum samples were collected in 2008 from 124
cats housed in two shelters, one in California (Sacramento) and one
in Michigan (Muskegon). These sera were tested for the presence of
Bartonella antibodies at two serial dilutions 1:32 and 1:64 by two of
the authors (BBC, RWK). A cat was reported serologically positive
when the scoring on a scale from 0 to 4 was $2 at the 1:64 dilution.
Uninfected cats had an IFA score range of 0.360.5 for B. henselae
and 0.560.6 for B. clarridgeiae at the 1:64 dilution and the IFA score
range at the 1:64 dilutionforinfected catswas2.061.3forB. henselae
and 2.860.8 for B. clarridgeiae. Of these cats, 62 were identified as
Bartonella blood culture negative and seronegative for Bartonella IgG
antibodies by an IFA test [16]. Another 62 cats were determined to
be either seropositive (IFA titer $1:64) or both IFA and culture
positive (24 of the 62 seropositive cats were also culture positive).
Similarly, serum samples from 8 Bartonella-uninfected (‘‘specific
pathogen free [SPF]’’) cats were submitted for testing and were both
culture and IFA negative. Cats ranged in age from ,3 months to
adult (average uninfected cat age was approximately 19.9 months
old with a standard deviation of 19.7 months; average infected cat
agewasapproximately19.4monthsoldwith a standard deviationof
20.3).
PCR amplification of linear acceptor vector
Each predicted open reading frame (ORF) from the B. henselae
genome sequence was amplified from B. henselae JK33 strain DNA,
and was cloned into the pXT7 vector using a high-throughput
PCR cloning method previously described [6]. The pXT7 plasmid
(3.2 kb, KanR) encodes an N-terminal 10 x histidine (HIS) tag and
a C-terminal hemagglutinin (HA) tag. pXT7 (10 mg) was
linearized with BamHI (0.1 mg/ml DNA, 0.1 mg/mL BSA,
0.2 U/ml BamHI, Invitrogen) overnight at 37uC. The digest was
purified using a PCR purification kit (Qiagen, Valencia, CA),
quantified using a NanoDrop (Thermo Scientific), and verified by
agarose gel electrophoresis. PCR was used to generate the linear
acceptor vector in 50 ml PCR reactions with 0.5 mM of each
primer (CTACCCATACGATGTTCCGGATTAC and CTCG-
AGCATATGCTTGTCGTCGTCG). PCR was performed using
0.02 U/ml AccuPrime Taq DNA polymerase (Invitrogen),
0.2 mM of each dNTP, and 1 ng pXT7 diluted in AccuPrime
Buffer II. The following PCR conditions were used: 95uC for
5 min; 30 cycles of 95uC for 0.5 min, 50uC for 0.5 min, 72uC for
3.5 min; and a final extension at 72uC for 10 min.
Open reading frame cloning
Primers were designed to all 1,493 ORFs that did not contain
an internal stop codon (1493/1612), as predicted from the genome
sequence of the B. henselae Houston-1 strain (BX897699.1) [17].
PCR primers were designed for the 59 and 39 ends of each ORF,
with the addition of a 20 bp homologous recombination ‘‘adapter’’
sequence (ACGACAAGCATATGCTCGAG and TCCGGAA-
CATCGTATGGGTA respectively). The adapter sequences,
which become incorporated into the termini flanking the amplified
gene, are homologous to the cloning sites of the linearized T7
expression vector pXT7. ORFs that are larger than 3000 bp were
split into smaller fragments with 150 bp overlap for efficient
amplification. PCR reactions were prepared using 0.02 U/ml
AccuPrime Taq DNA polymerase (Invitrogen), 0.2 mM of each
dNTP, diluted in Buffer II, with 2.5 ng of B. henselae template
DNA, using the following conditions: 95uC for 2 min; 30 cycles of
95uC for 0.33 min, 55uC for 0.25 min, 50uC for 0.25 min, 68uC
for 3 min; and a final extension of 68uC for 10 min. All B. henselae
ORF-PCR reactions were confirmed by gel electrophoresis for
correct insert size prior to cloning into pXT7.
High-throughput recombination cloning
All ORFs amplified from B. henselae strain JK33R DNA were
cloned into the plasmid expression vector pXT7 using a high-
throughput PCR recombination cloning method previously
developed in our laboratory [6]. Linearized pXT7 was diluted
to 10 ng/ml, mixed with 1 mlo fB. henselae ORF PCR reaction
mixture at a volume ratio of 4:1, and incubated on ice for 2 min,
followed by addition of 10 ml of competent E. coli DH5a cells
(MCLabs). Reactions were mixed, incubated on ice for 30 min,
heat shocked at 42uC for 1 min, and chilled on ice for 2 min.
250 ml of SOC media was added and cells were incubated for 1 hr
at 37uC. The entire reaction mixture was added to 1.5 ml of LB
medium supplemented with 50 mg/mL of kanamycin, and
incubated overnight at 37uC with shaking. Plasmids were isolated
using QIAprep 96 Turbo kits (Qiagen, Valencia, CA) without
colony selection. Minipreps of all attempted clones were analyzed
by agarose gel electrophoresis to confirm insert size. 25% of all
clones were confirmed for insert size by PCR using ORF
sequence-specific primers. An additional 25% of all clones were
selected at random and sequenced in both directions. Sequences
were analyzed for fidelity, orientation, and for mutation in the
overlapping region of the homologous recombination sites. The
Bartonella Antigen Microarray
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11447cloning efficiency for all amplified ORFs was 98.4%, resulting in
1520 plasmids encoding proteins from 1464 ORFs.
Protein microarray chip printing
The expression of cloned ORFs was carried out for five hours in
in vitro transcription-translation (IVTT) reactions (RTS 100 kits,
Roche) according to the manufacturer’s instructions. Protein
microarrays were printed onto nitrocellulose-coated glass FAST
slides (Whatman) using an Omni Grid 100 microarray printer
(Genomic Solutions). 3.3 ml of 0.2% Tween-20 was mixed with
10 ml of IVTT and transferred to 384-well plates. Plates were
centrifuged at 16006 g to pellet any precipitate and remove air
bubbles prior to printing. Supernatants were printed immediately
without purification, and all ORFs were spotted in duplicate. Data
values reported herein represent an average of the pair, unless
otherwise mentioned. In addition, each chip was printed with
control spots consisting of IVTT reactions without plasmid,
purified IgGs, and purified EBNA1 proteins. Protein expression
was confirmed using monoclonal anti-polyhistidine (clone His-1,
Sigma) and anti-hemagglutinin (clone 3F10, Roche).
Microarray probing
Feline sera were preabsorbed with E. coli lysate prior to array
staining, to remove background reactivity to E. coli proteins in the
IVTT reactions. The sera were diluted to 1:200 in Protein Array
Blocking Buffer (Whatman) containing 15 mg/ml reconstituted E.
coli lysate (McLabs) and incubated at room temperature for 30
minutes with constant mixing. The arrays were rehydrated in
blocking buffer for 30 min and probed with the preabsorbed sera
overnight at 4uC with constant agitation. The slides were then
washed five times in 10 mM Tris (hydroxymethyl) aminomethane
buffer (pH 8.0) containing 0.05% (v/v) Tween-20 (TTBS), and
incubated in biotin-conjugated, goat anti-cat immunoglobulin
(anti-IgGfcc, Jackson Immuno Research) diluted 1/200 in
blocking buffer. After washing the slides three times in TTBS,
bound antibodies were detected by incubation with streptavidin-
conjugated SureLightH P-3 (Columbia Biosciences). The slides
were then washed three times in TTBS and three times in Tris
buffer without Tween-20 followed by a final water wash. The
slides were air dried after brief centrifugation and analyzed using a
Perkin Elmer ScanArray Express HT microarray scanner.
Immunostrip assay
Fifteen sequence-confirmed plasmids were expressed in five-
hour IVTT reactions, according to the manufacturer’s instruc-
tions. Proteins were printed on Optitran BA-S 85 0.45 mm
Nitrocellulose membrane (Whatman) using a BioJet dispenser
(BioDot) at 1 ml/cm, and cut into 3 mm strips. Individual strips
were then blocked for 30 minutes in 10% non fat dry milk
dissolved in TTBS. Prior to immunostrip probing, cat sera were
diluted 1:250 in 10% nonfat dry milk solution containing 15 mg/
ml E. coli lysate, and incubated for 30 min with constant mixing at
room temperature. Preabsorbed sera were then applied to each
strip and incubated overnight at 4uC with gentle mixing. Strips
were washed five times in TTBS, and then incubated for 11hour at
room temperature in alkaline phosphatase conjugated goat anti-
cat immunoglobulin (anti-IgG, Fcc fragment-specific, Jackson
ImmunoResearch), that was diluted to 1:5000 in TTBS. The strips
were then washed three times in TTBS, followed by another three
washes in Tris buffer without Tween-20. Reactive bands were
visualized by incubating with 1-step Nitro-Blue Tetrazolium
Chloride/5-Bromo-4-Chloro-39-Indolyphosphate p-Toluidine Salt
(NBT/BCIP) developing buffer (Thermo Fisher Scientific) for 2.5
minutes at room temperature. The enzymatic reaction was
stopped by washing the strips with tap water. Strips were air
dried and scanned at 2,400 dpi (Hewlett-Packard scanner). Images
were converted to gray scale format by Photoshop and unaltered
images are shown. Band intensities were quantified using ImageJ
software [18] (found at http://rsbweb.nih.gov/ij/).
Data and statistical analysis
The protein microarrays used here do not meet the criteria for
required deposition under MIAME guidelines [19], and alterna-
tives to standardize protein microarray results are in development
to insure that all information can be easily interpreted (description
of minimum information about a proteomics experiment
[MIAPE] can be found here [20]). Intensities were quantified
using QuantArray software utilizing automatic background
subtraction for each spot. Proteins were considered to be expressed
if either tag’s signal intensity was greater than the average signal
intensity of the IVTT reaction without plasmid, plus 2.5-times the
standard deviation. ‘‘No DNA’’ controls consisting of IVTT
reactions without addition of plasmid were averaged and used to
subtract background reactivity from the unmanipulated raw data.
All results presented are expressed as signal intensity. As previously
reported [21], the ‘‘vsn’’ package in the Bioconductor suite
(http://Bioconductor.org/) in the R statistical environment
(http://www.R-project.org) was used to calculate seroreactivity.
In addition to the variance correction, this method calculates
maximum likelihood shifting and scaling calibration parameters
for different arrays, using known non-differentially expressed spots.
This calibration has been shown to minimize experimental effects
[22]. We used raw values for the positive and negative controls to
calibrate, and then normalize, the entire data set using the vsn
package. Differential analysis of the normalized signals was then
performed using a Bayes-regularized t-test adapted from Cyber-T
for protein arrays [23,24,25,26]. Benjamini-Hochberg p-value
adjustments were applied to account for multiple test conditions
[27]. All p-values shown are Benjamini-Hochberg corrected for
false discovery, unless otherwise noted. Multiple antigen classifiers
were built using Support Vector Machines (SVMs). The ‘‘e1071’’
and ‘‘ROCR’’ packages in R were utilized to train the SVMs and
to produce receiver operating characteristic curves, respectively.
Computational prediction of transmembrane domains utilized
the TMHMM v2.0 software [28] (http://www.cbs.dtu.dk/servic-
es/TMHMM/); signal peptide prediction used SignalP v3.0
software [29] (http://www.cbs.dtu.dk/services/SignalP/); cellular
location prediction utilized PSORTb v2.0.4 software [30] (http://
www.psort.org/psortb/); predicted isolectric point was determined
using Swiss Institute of Bioinformatics pI/MW software (http://
ca.expasy.org/tools/pi_tool.html); and codon adaptation index
(CAI) of each protein was retrieved from JCAT program (http://
www.jcat.de)[31]. The COG information utilized can be found at
http://www.ncbi.nlm.nih.gov/sutils/coxik.cgi?gi=409. Enrich-
ment statistical analysis was performed in the R environment,
using Fisher’s exact test. Segmented ORFs were considered
seroreactive if any segment was identified as seroreactive.
Results
Construction and probing of a Bartonella henselae
protein microarray with sera from infected and
uninfected cats
A protein microarray comprised of 4032 spots from 1433 ORFs
spotted in duplicate, with positive and negative controls was
fabricated, as described in Methods. IVTT expression efficiency
was determined by probing against the amino-terminal HIS and
carboxy-terminal HA tags for each spot (Fig. 1a and 1b). 95.1% of
Bartonella Antigen Microarray
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greater than the average of ‘‘No-DNA’’ control reactions plus 2.5
times the standard deviation, and were considered positively
expressed. Sera from cats housed in two animal shelters were used
to probe the B. henselae protein microarray in order to map the feline
host anti-B. henselae antibody profile after naturally acquired
infection. The B. henselae protein microarray was probed with a
collection of 132 cat sera. Sixty-two cats identified as seropositive or
seropositive and culture-positive were compared to 62 cats identified
as seronegative and culture negative. The seronegative and culture
negative cats could have been exposed earlier in their lives to
Bartonella species and cleared the infection, with either lack of
antibody titers or titers below the positive threshold (score of 2 or
more at 1:64 dilution). Additionally, the array was probed with 8
Bartonella-free cat sera (from cats never exposed to Bartonella)t o
establish non-specific reactivity. In total, microarray data from 132
cat sera were used to generate a profile of host reactivity to B. henselae
infection. Representative images of protein microarrays probed with
sera from B. henselae-infected and naı ¨ve cats samples are shown in
Figure 1c and 1d. Signal intensities of duplicate spots were recorded
and averaged for each antigen and for each cat serum, individually.
Antigens were considered seroreactive if the average signal intensity
exceeded the average signal intensity of the IVTT reaction without
plasmid (No-DNAcontrols) plus2.5-timesthe standarddeviation. As
expected, duplicate spots were highly correlative with a total R
squared of 0.99, similar to our previous published results from a
Chlamydia trachomatis protein microarray [32].
Profile of humoral immune response to the Bartonella
henselae proteome
The antibody response profile to B. henselae in its natural cat host
is shown as a heatmap for both infected and uninfected cats
Figure 1. Construction of a B. henselae protein microarray. Arrays were printed containing 4032 spots from B. henselae proteins, as well as
positive and negative control spots. Proteins were printed in duplicates and average signal intensities were calculated. Each array contains positive
control spots printed from 6 serial dilutions of purified IgG, 6 serial dilutions of EBNA1 protein, and 6 ‘‘No DNA’’ negative control spots. The array was
probed with anti-His antibody (A) or anti-HA antibody (B) as described in Materials and Methods, to confirm the expression and printing of 1433 B.
henselae ORFs. (C and D) Comparison of arrays probed with naı ¨ve serum and positive serum. The arrays were read in a laser confocal scanner,
analyzed, and the data normalized as described in Materials and Methods. The signal intensity for each antigen is represented by a rainbow palette of
blue, green, red and white, corresponding to increasing signal.
doi:10.1371/journal.pone.0011447.g001
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seroreactive. Cellular localization prediction of seroreactive ORFs
revealed that 34 of 105 contained a signal peptide. Twenty-three
were predicted to be localized to the cytoplasm, 21 to the
cytoplasmic membrane, 9 to the outer membrane, 3 were
periplasmic, and 49 were unable to be predicted by PSORTb.
The mean reactivity for each protein on the array was compared
between the infected and uninfected groups and plotted as a
histogram (Fig. 3). Fifty-two antigens were differentially reactive
(p,0.05), and 53 antigens were cross-reactive (p.0.05) between
infected and uninfected cats. All of the sera reacted similarly to the
cross-reactive antigens whether from infected or uninfected cats.
Mean reactivity of seroreactive antigens was correlated to IFA
score, and the Pearson’s R was determined to be 0.70 for
differentially reactive antigens and 0.17 for cross-reactive antigens,
indicating a strong association with current IFA diagnostic assays
and the identified differentially reactive antigens. A complete list of
all seroreactive antigens is shown in Table S1. Twenty-four of the
62 seropositive cats were culture positive. The average seroreac-
tivity from cats that were seropositive and culture positive was not
significantly different from the average seroreactivity of cats that
were seropositive and culture negative for either differentially
reactive or cross-reactive antigens (Student’s t-test p-value =0.75
and 0.36, respectively).
Bartonella henselae type-specific immune response
Differential antibody profiles were investigated for type I and
type II B. henselae (Fig. 4). Of the cat sera profiled by microarray,
10 were B. henselae type I and 14 were B. henselae type II. Thirteen
antigens were statistically differentially reactive between these two
groups for all 105 seroreactive antigens (Student’s t-test p-value
,0.05). The other 92 were equally reactive, including the two
most reactive antigens (BH13530 (MopA) and BH07870 (LemA)).
B. henselae type I cats were most significantly differentially reactive
to BH01250 (CyoD) and BH13260 (VirB2, p=5.5610
23 and
5.0610
23). BH01250 is the 6
th most reactive antigen, and
BH13260 is the 23
rd most reactive antigen of the infected cat
group. BH12700 (VceA) is the 5
th most reactive antigen of the
infected cat group and had a mean signal intensity of 25k. The
mean reactivity for B. henselae types I and II was 29 k and 21 k,
respectively, suggesting that the distribution of type I and type II
infected cats was evenly represented among the 62 infected cats.
The same was true for the second most type-specific differentially
reactive antigen (BH01250). BH01250 had a mean signal intensity
of 24 k, and B. henselae types I and II had signal intensities of 37 k
and 18 k, respectively. One antigen (BH11090) was found to be
significantly more reactive in the type II infected cat group than in
the type I infected group (p-value=1.7610
22).
Validation of seroreactivity with immunostrips
In order to validate the seroreactivity of the protein microarrays
and to test the feasibility of using serodiagnostic antigens in an
alternative analytical diagnostic assay, 15 antigens were printed
onto nitrocellulose membranes, referred to as immunostrips.
These 15 antigens were chosen for being highly significant and
highly seroreactive by protein microarray. Individual immuno-
strips were probed with 30 infected and 28 uninfected cat sera
chosen from the collection at random (Fig. 5). Bartonella-infected
cat sera reacted strongly with the differentially reactive antigens,
although the intensity pattern varied depending on the individual
cat. Uninfected cat sera had low reactivity with these antigens, and
produced a different pattern of reactivity than infected cats.
Quantitative analysis of the immunostrips was used to directly
compare seroreactivity of infected and uninfected cats on the
immunostrips platform. The three most differentially reactive
antigens in the protein microararay BH13530, BH07870,
BH12700 (p-value=7.0610
214, 2.3610
213, and 3.3610
28,
respectively) were also the most significantly different in the
immunostrip, showing validation of the microarray and transfer-
ence to a separate diagnostic platform (p-value =1.39610
214,
Figure 2. Probing a collection of B. henselae infected, uninfected, and SPF control cat sera. Arrays containing 1433 B. henselae proteins
were probed with cat sera organized into 3 groups as described in the text. Heatmap showing normalized intensity with red strongest, bright green
weakest, and black in between. Cat samples are in columns and sorted left to right by increasing average intensity to differentially reactive antigens,
and antigens are listed in rows sorted by decreasing average seroreactivity of infected cats. Only seroreactive antigens are displayed (n=105).
Seroreactivity is higher in the infected cats against differentially reactive antigens, but equally reactive in the cross-reactive antigen set.
doi:10.1371/journal.pone.0011447.g002
Bartonella Antigen Microarray
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213, and 4.0610
210 respectively). Furthermore, the
immunostrips were probed with SPF naı ¨ve sera to confirm and
evaluate background reactivity in uninfected cats. As expected,
SPF naı ¨ve cats displayed minimal reactivity to all bands, similar to
most of the uninfected group.
Serodiagnostic accuracy
In order to determine the diagnostic ability of the differentially
reactive antigens, we used kernel methods and support vector
machines [33,34] to build linear and nonlinear classifier from
microarray and immunostrips data. As such, we utilized the
discriminatory power of multiple ORFs in order to assess their
ability to separate uninfected from infected sera. Serodiagnostic
antigens were ranked according to p-value with the top 3 antigens
having p-values less than 7.0610
214 (Table S1). We input the
most significantly different antigens in sets of 1, 2, 3, 4, 5, 10, 25,
and 52 antigens on the basis of p-value. The boxplots for these
predictions were plotted and the results show that increasing the
number of antigens from 1 to 2, and 2 to 3 produces an
improvement in the classifier (Fig. 6). The classifier was able to
accurately predict 93% of infected cats using 3 antigens.
Increasing the diagnostic set from 3 to 4 antigens produced no
increase in accuracy, and increasing past 4 antigens results in a
reduction in accuracy due to over-fitting.
A subset of sera that was tested on the microarray platform was
selected at random and demonstrated seroreactivity on the
immunostrip platform. In order to determine the potential
diagnostic utility of these differentially reactive antigens, quantified
Figure 3. Discovery of cat serodiagnostic antigens. The 30 most reactive serodiagnostic and differentially reactive antigens are plotted on the
x-axis. The mean seroreactivity of each antigen was compared between the infected (n=62) and uninfected (n=62) groups plotted in blue and red,
respectively, with SEM. Corresponding p-values for each antigen are shown as a green line on the secondary y-axis.
doi:10.1371/journal.pone.0011447.g003
Figure 4. Differential seroreactivity of B. henselae type I and II cats. Mean seroreactivity of B. henselae type I (n=10) and type II (n=14) are
plotted in blue and red, respectively. Corresponding SEM and p-values on the secondary y-axis are shown for each antigen. All nine differentially
reactive antigens and the 30 most reactive cross-reactive antigens are plotted on the x-axis. Antigens are sorted left to right by decreasing
seroreactivity of B. henselae type I infected cats.
doi:10.1371/journal.pone.0011447.g004
Bartonella Antigen Microarray
PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11447immunostrip results were used to build a classifier and accuracy was
determined, as shown in Figure 6. As in the microarray classifier,
increasing the number of antigens produced a more accurate
diagnosticclassifieruntilapeakwasreachedfollowedbyareduction
in accuracy due to over-fitting. We found that the most accurate
diagnostic ability utilized 4 antigens and produced a diagnostic
accuracy capable of identifying 98% of the infected cats. Differences
in accuracy and the number of antigens that increase the diagnostic
accuracy between immunostrips and microarrays are an expected
result from utilizing different platforms for diagnostics.
Figure 5. Immunostrips probing. Fifteen serodiagnostic antigens were printed onto nitrocellulose paper in adjacent stripes using a BioDot jet
dispenser as described in Materials and Methods. Strips were probed with infected and uninfected sera diluted 1/200 followed by alkaline
phosphatase conjugated secondary antibody and enzyme substrate. Weak reactivity in uninfected controls can be distinguished from the strong
reactivity in the infected group. A red dot under the 5
th,1 0
th, and 15
th antigen is indicated as a guide marker.
doi:10.1371/journal.pone.0011447.g005
Figure 6. Multiple antigen classifier. The boxplots show classifiers with increasing number of serodiagnostic antigens. (a) Boxplots for the
microarray classifier using the top 1, 2, 3, 4, 5, 10, 25, 52 antigens (b). The ROC curves were generated for each antigen set and a maximum predictive
accuracy of 93%. ROC curves show that accuracy increases as multiple antigens are used to generate the classifier when increasing from 1 to 2
antigens, and from 2 to 3 antigens. (c) Boxplots for the classifier using the immunostrips are plotted. (d) A comparison of the ROC curves for the
diagnostic accuracy of the microarray platform using 3 antigens compared to the ROC curve of immunostrips using 4 antigens.
doi:10.1371/journal.pone.0011447.g006
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We next classified the serodiagnostic and cross-reactive antigens
according to their annotated and computationally predicted
features. The summary of this analysis can be found in Table 1.
The NCBI database of Clusters of Orthologous Groups of proteins
(COGs) was used for annotation. Each COG consists of individual
proteins or groups of paralogs from at least 3 lineages, and is
comprised of 25 categories of functional definitions. Each protein
in the database is assigned to one or more COGs, with a total of
1569 COGs assigned to the 1433 ORFs on the array. The results
in Table 1 illustrate that reactivity is not evenly distributed
between various COGs and some are much more likely to contain
seroreactive ORFs. For example COG V, containing proteins
involved in defense mechanisms, was found to be enriched for
seroreactive ORFs (4.20 fold enrichment, p-value =2.9610
22). In
contrast, COG E (amino acid transport and metabolism)
contained no seroreactive proteins, despite the presence of 100
COG E ORFs in our array. Underrepresentation was also found
in proteins involved in transcription (1/78 or 1.3%, p-val-
ue=3.9610
22) and translation (2/138 or 1.4%, p-val-
ue=2.9610
23). Analysis of individual COGs showed that no
category was entirely reactive. For instance, the most predictive
COG (COG U - intracellular trafficking and secretion) contained
only 23.5% seroreactive proteins (16/68, 3.30 fold enrichment, p-
value=1.0610
25). The next most predictive COG (COG M - cell
wall/membrane biogenesis) contained 17.7% seroreactive proteins
(16/90, 2.49 fold enrichment, p-value=3.8610
24). Utilization of
the COG database allowed characterization of functional group
enrichment and under-representation; however, 292 B. henselae
proteins were not defined by the COG database. Interestingly, this
undefined category contained a significant number of seroreactive
proteins (32/292, 1.54 fold enrichment, p-value=7.7610
23)
compared to ORFs that were grouped into various COGs (80/
1277, 0.88 fold enrichment, p-value=7.7610
23).
In addition to looking for COG enrichment, we also analyzed
enrichment based on subcellular localization of proteins. Locali-
Table 1. COG enrichment table.
Seroreactive Differentially reactive Cross-reactive
NCBI COG definition
Total on
array hits
Fold
Enrich p-value hits
Fold
Enrich p-value hits
Fold
Enrich p-value
A - RNA processing and modification 0 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
B - Chromatin structure and dynamics 0 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
C - Energy production and conversion 71 8 1.57 1.6E201 6 * 2.55 2.7E202 2 0.74 1.0E+00
D - Cell cycle control, mitosis and meiosis 22 3 1.91 2.0E201 1 1.37 5.3E201 2 2.38 2.0E201
E - Amino acid transport and metabolism 100 0 * 0.00 9.0E204 0 0.00 7.4E202 0 * 0.00 2.9E202
F - Nucleotide transport and metabolism 45 1 0.31 3.7E201 0 0.00 4.0E201 1 0.58 1.0E+00
G - Carbohydrate transport and metabolism 48 2 0.58 5.8E201 0 0.00 4.0E201 2 1.09 7.1E201
H - Coenzyme transport and metabolism 55 1 0.25 1.8E201 0 0.00 2.6E201 1 0.48 7.2E201
I - Lipid transport and metabolism 38 1 0.37 5.2E201 0 0.00 6.3E201 1 0.69 1.0E+00
J - Translation 138 2 * 0.20 2.9E203 1 0.22 8.1E201 1 0.20 5.5E202
K - Transcription 78 1 * 0.18 3.9E202 1 0.39 5.1E201 0 0.00 7.0E202
L - Replication, recombination and repair 80 4 0.70 6.5E201 0 0.00 1.1E201 4 1.31 5.4E201
M - Cell wall/membrane biogenesis 90 16 * 2.49 3.8E204 9 * 3.02 2.1E203 7 2.03 7.9E202
N - Cell motility 4 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
O - Posttranslational modification, protein turnover,
chaperones
70 11 * 2.20 1.4E202 7 * 3.02 7.0E203 4 1.49 3.4E201
P - Inorganic ion transport and metabolism 63 1 0.22 8.3E202 0 0.00 2.7E201 1 0.42 5.1E201
Q - Secondary metabolites biosynthesis, transport
and catabolism
12 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
R - General function prediction only 152 5 0.46 6.6E202 2 0.40 2.3E201 3 0.54 3.6E201
S - Function unknown 90 5 0.78 6.8E201 2 0.67 7.7E201 3 0.87 1.0E+00
T - Signal transduction mechanisms 39 0 0.00 1.1E+00 0 0.00 6.4E201 0 0.00 3.9E201
U - Intracellular trafficking and secretion 68 16 * 3.30 1.0E205 8 * 3.55 1.3E203 8 * 3.23 2.5E203
V - Defense mechanisms 10 3 * 4.20 2.9E202 2 * 6.03 4.1E202 1 2.75 3.1E201
W - Extracellular structures 4 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
Y - Nuclear structure 0 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
Z - Cytoskeleton 0 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
Not in COGs 292 32 * 1.54 7.7E203 16 * 1.65 2.9E202 16 1.50 8.7E202
Total COGs 1569 112 55 57
Enrichment table of COG functional groups for seroreactive, serodiagnostic, and cross-reactive antigens. The numbers of annotated proteins printed on the array for
each COG are totaled under ‘‘Total on array.’’ Seroreactive, serodiagnostic, and cross-reactive annotated proteins are totaled as ‘‘counts’’. Asterisks denote significant
values.
doi:10.1371/journal.pone.0011447.t001
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From our entire ORF collection, pSORTb predicted 28 outer
membrane proteins, of which 9 were seroreactive (32%). This was
the most enriching feature based on localization (4.39 fold
enrichment, p-value=9.2610
25). Conversely and as expected,
we found pSORTb predicted cytoplasmic proteins were signifi-
cantly underrepresented (0.63 fold enrichment, p-val-
ue=2.9610
23). Interestingly, the pSORTb predicted periplasmic
proteins, as well as proteins in COG categories C, M, and O, were
significantly enriched in only differentially reactive antigens, but
not in cross-reactive antigens. These categories may prove useful
for in silico prediction of potentially protective antigens and
diagnostics. Proteins predicted to have isoelectric points between 5
and 7 are significantly underrepresented in the seroreactive group
(0.69 fold enrichment, p-value=1.5610
22). This group is
comprised of differentially reactive and cross-reactive proteins, in
which only the cross-reactive proteins are significantly underrep-
resented (0.54 fold enrichment, p-value=7.3610
23), and would
be poor targets for in silico predictors of diagnostic antigens. We
found that more acidic proteins are less likely to be seroreactive
and are more likely to be located in the cytoplasm, which may
explain their underrepresentation. Proteins predicted to have
isoelectric points between 5–7 were also significantly underrepre-
sented in seroreactive and cross-reactive groups.
Some molecules can be expressed at high levels in vivo making
them more likely targets for immune recognition, independent of
their functional category. In order to determine the validity of this
assumption, we looked at frequency distribution of codon
adaptation index (CAI). Generally, higher CAI-values reflect
potentially higher expression levels of an ORF. The CAI-values of
B. henselae range from 0.27 to 0.71. While we found significance in
ORFs that score in the middle on the CAI index range (from 0.4
to 0.5, fold enrichment 1.28, p-value= 3.4610
22), we were
surprised to find that antigens with high CAI values (which tend to
be over-expressed) were not significantly enriched (Table 2). The
bias for identifying highly expressed proteins discovered using 2D
gels could be an inherent artifact not found using in vitro expression
based platforms, like protein microarrays.
Discussion
Our results represent a large-scale analysis of B. henselae proteins
that are immunogenic in the context of naturally acquired feline
infection. We have constructed the first protein microarray for B.
henselae, which allowed us to assess the humoral immune response
to B. henselae from 62 naturally infected cats. The seroreactive
antibody profile revealed many unknown seroreactive antigens,
and confirmed previously identified ones. In this research, we
sought to identify potentially protective and diagnostically relevant
B. henselae antigens, and to understand the repertoire of the
humoral immune response to infection in the natural feline host
reservoir. In a genetically diverse population, the antibody
repertoire is expected to vary among individual cats. Despite this
diversity, the subset of differentially reactive antigens we identified
Table 2. Computationally predicted feature enrichment table.
Seroreactive Differentially reactive Cross-reactive
Computational Predictions
Total on
array hits
Fold
Enrich p-value hits
Fold
Enrich p-value hits
Fold
Enrich p-value
TMHMM = 0 1088 50 * 0.63 6.6E205 27 * 0.68 1.8E204 23 * 0.57 2.3E207
TMHMM $1 345 55 * 2.18 6.6E211 25 * 2.00 1.8E204 30 * 2.35 2.5E207
TMHMM $5 74 1 * 0.18 3.8E202 0 0.00 1.7E201 1 0.34 3.6E201
TMHMM $10 0 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
SignalP $0.7 (contains signal peptide) 194 34 * 2.39 3.0E207 19 * 2.92 4.3E206 15 * 1.94 8.6E203
SignalP ,0.7 1239 71 * 0.78 3.0E207 33 * 0.73 1.7E205 38 * 0.83 3.4E203
PSORTb Cytoplasmic 502 23 * 0.63 2.9E203 16 0.88 5.6E201 7 * 0.38 3.8E204
PSORTb CytoplasmicMembrane 229 21 1.25 2.7E201 11 1.32 3.3E201 10 1.18 5.7E201
PSORTb Extracellular 2 0 0.00 1.0E+00 0 0.00 1.0E+00 0 0.00 1.0E+00
PSORTb OuterMembrane 28 9 * 4.39 9.2E205 5 * 5.33 1.9E203 4 * 3.59 2.3E202
PSORTb Periplasmic 19 3 2.15 1.6E201 3 * 4.71 2.3E202 0 0.00 1.0E+00
PSORTb Unknown 653 49 1.02 8.4E201 17 0.72 6.5E202 32 * 1.32 3.4E202
isoelectric point pI 0–5 82 9 1.49 1.9E201 6 2.02 1.2E201 3 0.99 1.0E+00
isoelectric point pI 5–7 511 26 * 0.69 1.5E202 15 0.88 6.5E201 11 * 0.54 7.3E203
isoelectric point pI 7–9 323 26 1.10 5.5E201 12 1.02 8.7E201 14 1.17 5.0E201
isoelectric point pI 9–14 517 44 1.16 2.1E201 19 1.01 1.0E+00 25 1.31 1.1E201
CAI 0.0–0.4 36 0 0.00 1.1E201 0 0.00 6.3E201 0 0.00 6.4E201
CAI 0.4–0.5 512 48 * 1.28 3.4E202 22 1.18 3.1E201 26 * 1.37 4.2E202
CAI 0.5–0.6 798 53 0.91 2.6E201 27 0.93 5.7E201 26 0.88 3.3E201
CAI 0.7–1.0 87 4 0.63 4.0E201 3 0.95 1.0E+00 1 0.31 3.7E201
Total ORFs 1433 105 52 53
Enrichment table of computationally predicted functional groups for seroreactive, serodiagnostic, and cross-reactive antigens. The numbers of proteins printed on the
array for each predicted feature are totaled under ‘‘Total on array.’’ Seroreactive, serodiagnostic, and cross-reactive proteins with predicted features are totaled as
‘‘counts’’. Asterisks denote significant values.
doi:10.1371/journal.pone.0011447.t002
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henselae exposed cats using the microarray (and 98% with the
immunostrips), and it is likely that this set of antigens will form the
basis of new and more accurate serodiagnostic assays for Bartonella
exposure. Additionally, utilization of these antigens in alternative
platforms (e.g., ELISA format) may provide an easy, universal, and
rapid diagnostic assay. Importantly, some of the antigens we have
discovered could be ideal candidates for generating subunit
vaccines that protect cats from infection, thus limiting the
morbidity and mortality of incidental human infections. All
differentially reactive antigens, as well as the level of differential
seroreactivity are not expected to correlate with protection, and
empirical evaluation of selected, differentially reactive antigens will
have to be determined. Of note, vaccination with facultatively
intracellular pathogens, like B. henselae, could also depend on
effective T-cell memory for mediating host defense and production
of specific antibodies. Our study investigated the immune response
of cats at a single time point, and we were not able to document
previous infection of these cats by other Bartonella species or
genotypes, including B. clarridgeiae or B. koehlerae, for which some
cross-reactivity may occur [1]. Therefore, in some cats, the
antibody profile could represent undetected coinfection or
superinfection. In fact, protection of cats from infection with both
B. henselae type I and type II would be ideal, because both types
cause human zoonotic infections.
The most differentially reactive antigens on the immunostrips
were able to accurately predict 98% of infected cats using 3
antigens (MopA, VceA, and LemA). Inclusion of the next highest
ranked antigen, VirB8 (a type IV secretion system [T4SS]
molecule), did not significantly improve the predictive accuracy.
Antigens that are involved in T4SS are key factors in mediating
Bartonella-host cell interactions, and five T4SS components are
found in the serodiagnostic set (TrwE, TrwG, VirB2, VirB8, and
VirB10). Interestingly, no T4SS molecules were found in the cross-
reactive antigen set. T4SS is comprised of a protein complex that
is used to transport effector molecules directly into the host target
cell. T4SS molecules are attractive targets for the development of
new therapeutic agents, and investigation of monoclonal antibody
therapy or small molecule inhibitors to block the secretion of
virulence factors could provide protection or limit disease. The
cross-reactive protein ParA is a plasmid partitioning protein, and
the gene encoding this protein was previously identified as the only
unique gene absent in B. quintana, although it is present in the
genomes of both B. koehlerae and B. henselae [35]. Lindroos, et al.,
believe it is a pseudogene and not involved in host specificity,
because the gene is shorter than normal in B. henselae and it is not
flanked by a homolog to parB, as are most other parA genes. The
role of this protein in association with the feline pathogen remains
to be investigated, as well as its role in establishing acute and
chronic infection. BH12700 (VceA, a multidrug resistance gene),
and BH13260 (VirB2, a T4SS molecule), are both differentially
reactive between genotypes I and II, and could facilitate an
understanding of the differences between the two types. Experi-
mental infection with B. henselae type I or type II in SPF cats
provides complete protection against a challenge with the same
genotype [3,36]. However B. henselae type I provides partial
protection from a challenge with B. henselae type II. On the
contrary cats infected with B. henselae type II were not protected
when challenged with the heterologous strain, B. henselae type I
[37]. The two most differentially reactive antigens are equally
reactive in both types I and II, and subunit vaccines including
these antigens should be ideal candidates for protection against
both types I and II of B. henselae. Further investigation of the
antibody profiles of protected and non-protected SPF cats could
provide insight into individual antigens or profiles of antigens
responsible for mediating cross-protection against both types, as
our study was a cross-sectional study and some of the bacteremic
cats may have had a previous infection with the other B. henselae
genotype or even with other Bartonella species leading to
production of cross-reactive antibodies [37].
We found that reactivity was not evenly distributed across the
proteome and no individual category was completely seroreactive
(Table 1). Cross-reactive and differentially reactive antigens are
selectively enriched or underrepresented from specific functional
categories. As expected, outer membrane proteins are more likely
to be seroreactive (4.39 fold enrichment, p-value=9.2610
25) and
account for 8.6% of reactive antigens, but represent only 2.0% of
the proteins on the array. As expected, antigens predicted to be
cytoplasmic are significantly underrepresented (comprising only
4.6% of total seroreactive antigens, but constitute 34.8% of the
proteins on the array). While these results classifying antigenicity
by protein localization are consistent with expectations, they
provide a quantitative and more informative understanding than
previously reported. Importantly, there is no category that is
entirely reactive, although there are some categories that are
entirely unreactive. For example, there are 100 ORFs that are
involved in amino acid transport and metabolism, but none of
these antigens were seroreactive. Moreover, we found ORFs
involved in translation and transcription to be significantly less
likely to be seroreactive (p-value=2.9610
23 and 3.9610
22,
respectively). Antigens predicted to contain at least one trans-
membrane domain were highly significantly enriched on the array
(2.18 fold enrichment, p-value=6.6610
211). Conversely, antigens
that were predicted to not contain a transmembrane domain were
significantly underrepresented (0.063 fold enrichment, p-value
6.6610
25). Identification of categories that are non-reactive is
important for understanding immune evasion and pathogenicity,
and is also valuable for developing exclusion criteria of in silico
prediction algorithms. Similarly, cross-reactive antibodies may
target identical proteins (or common epitopes) of both related and
unrelated bacteria, and are thought to exist as a consequence of an
indiscriminate or broad antibody response against numerous
bacteria, whether symbiotic, environmental, or other. Moreover,
cross-reactivity does not need to occur between closely related
organisms, but can also occur between phylogenetically distant
species. In this report, we identify numerous cross-reactive
antigens in a cat population, which may be important for
improved diagnostics and vaccine development. These results
are consistent with our previously published results detailing the
seroreactive profile of Burkholderia pseudomallei [21], another
proteobacteria member. We again found significant enrichment
of surface, chaperones, and PSORTb-predicted extracellular and
outer membrane proteins. Moreover, inclusion of a predicted
signal peptide or transmembrane domain were both enrichment
features. Proteins predicted by PSORTb to be cytoplasmic or of
unknown localization, and proteins predicted to not contain
transmembrane domains were also significantly underrepresented
in our previous profiling of seroreactive antigens from Burkholderia
infected patients [21].
A comprehensive profile of the antibody repertoire to an
infectious agent can provide new insight into disease pathogenesis.
The data reported here provide specific insight into the antigens
that are recognized by the humoral immune response after natural
infection(s) in a naturally infected cat population. We found that
the humoral immune response is not stochastic, and targets a
diverse collection of antigens. The results presented here confirm
that proteomic features can help predict seroreactive antigens, but
these predictions are imperfect because the majority of proteins
Bartonella Antigen Microarray
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repertoire against the comprehensive B. henselae proteome
highlights the need for an improved understanding of seroreac-
tivity determinants. Finally, our characterization of the feline
antibody repertoire generated during B. henselae infection provides
novel insight and utility in diagnostics, vaccine development, and
in understanding the host-pathogen interaction of a zoonotic
infectious agent.
Supporting Information
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